3SBio Inc.
1530
주식 순위
#3687
Operating as an investment holding company, 3SBio Inc. specializes in the full... Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.
주가
$1.83
시가총액
$4.57B
변동 (1일)
-2.79%
변동 (1년)
-50.11%
국가
CN
거래 3SBio Inc. (1530)
카테고리
Healthcare
3SBio Inc. (1530)의 수익
Jun 2026 기준 수익 TTM: $1.53B
3SBio Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $1.53B입니다. 2023년에 회사는 $279.50M의 수익을 올렸으며 이는 2022년의 수익 $329.67M과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
3SBio Inc.의 수익 기록 (2012 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $1.53B | 310.18% |
| 2024 | $372.39M | 33.23% |
| 2023 | $279.50M | -15.22% |
| 2022 | $329.67M | 12.12% |
| 2021 | $294.02M | 96.17% |
| 2020 | $149.88M | -14.66% |
| 2019 | $175.64M | -19.22% |
| 2018 | $217.41M | 28.36% |
| 2017 | $169.38M | 38.34% |
| 2016 | $122.44M | 35.25% |
| 2015 | $90.53M | 55.68% |
| 2014 | $58.15M | 69.01% |
| 2013 | $34.41M | 64.53% |
| 2012 | $20.91M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $5.27B | 245.34% |
US
|
|
| $-3.09B | -302.10% |
US
|
|
| $-4.02B | -362.93% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 27.71% |
NL
|
